Latest News and Press Releases

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer...

Arletta Pharma reports >60% clitoral blood flow improvement with Lybrido™ in Phase II study, achieving statistical significance in women with FSIAD.

MIAMI, March 27, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas...

RenX Enterprises (NASDAQ: RENX) is now trading post 1-for-20 reverse stock split

sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline...

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases,...

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and...

Record Quarterly Revenues of $737.6 Million, a 34.6% Increase from a Year Ago Quarterly Adjusted EBITDA (non-GAAP) Increased 53% from Prior Year1 Record Total Backlog and Awards of $3.7 Billion, 49%...

WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer ...